Skip to main content
Equibles
YCBD logo

YCBD · cbdMD, Inc. · Metrics

Track YCBD — free

Use YCBD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.49 -0.01 (-1.56%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company’s ability to continue as a going concern is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that these financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$5.33M
Shares
11.21M

YCBD metrics

65 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.50
Market cap
$5.33M

Price action

20 metrics
Price change (1W)
-4.9%
Price change (30D)
-16.0%
Price change (3M)
-34.3%
Price change (6M)
-39.0%
Price change (YTD)
-64.8%
Price change (1Y)
-33.9%
Trailing year
Price change (5Y)
—
52-week high
$2.27
52-week low
$0.47
Change from 52-week high
-79.0%
Change from 52-week low
+1.2%
Annualized volatility
194.3%
Annualized volatility (3M)
69.2%
Beta
0.8
RSI (14D)
38.4
Price vs SMA 50
-17.4%
Price vs SMA 200
-39.2%
Avg volume (3M)
212,253
Relative volume
0.4
Average dollar volume
$126,880

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
11.21M

Valuation

12 metrics
P / E (TTM)
12.3
Trailing earnings · reciprocal yield 8.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 392.8%
P / book
0.6
reciprocal yield 154.1%
FCF yield
-45.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-54.2%

Historical valuation

8 metrics
P / E historical average (3Y)
5.0×
reciprocal yield 20.1%
P / E historical average (5Y)
5.0×
reciprocal yield 20.1%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
81.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-30

Profitability

9 metrics
Gross margin
57.7%
Operating margin
-13.9%
Trailing 12 months
Net margin
-13.8%
Gross profit (TTM)
$12.07M
Operating profit (TTM)
−$2.90M
Net income (TTM)
−$2.89M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-11.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$38.47

Growth

11 metrics
Revenue growth YoY
+20.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$20.93M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+120.1%
Year over year · more shares
Revenue CAGR (3Y)
-18.5%
Revenue CAGR (5Y)
-14.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-35.2%
Return on assets
-22.0%
Debt / equity
—
Current ratio
2.5
EBITDA (TTM)
−$69.23M
Free cash flow (TTM)
−$2.41M
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.12M
Total assets
$13.15M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.22M
Capital expenditures (TTM)
$191,419
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$1.64M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
27
13F filer change QoQ
+2
Institutional ownership
8.2%

Short interest

3 metrics
Short interest
4.4%
Latest settlement · 2.0 days to cover
Days to cover
2.0d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1644903 CUSIP 12482W408 13F (30d) 16 filings 16 filers Visit website Investor relations